Fierce Biotech News & Reports
3 days ago · Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on Fierce Biotech as their must-read source for the latest news, analysis and …
Notable goes bankrupt, ending plans for Boehringer cancer drug
Oct 15, 2024 · Notable Labs’ attempts to take a Boehringer Ingelheim cancer drug to market appear to have come to end with the oncology-focused platform company’s decision to file for …
Fierce Biotech Layoff Tracker 2024
March—18 companies. March 29 - Mustang Bio: Cell therapy-focused Mustang has laid off an undisclosed number of workers. The company declined to disclose how many employees …
FDA approves Novocure’s tumor field therapy for metastatic NSCLC
Oct 16, 2024 · Novocure submitted Optune Lua for FDA review in NSCLC in December 2023, after also seeking a CE Mark approval in Europe. Around the same time—and following the …
Novartis inks $150M deal for autoimmune molecular glue
Oct 28, 2024 · Don’t stop Monte Rosa Therapeutics now. The Boston-based biotech is having a ball after signing a deal with Novartis to the tune of $150 million for a molecular glue degrader, …
Rectify drug repairs bile composition in mice with liver disease
Oct 22, 2024 · Rectify Pharma is using its ABCs to treat PSC. Three years after raising $100 million in series A funds, the Atlas Venture-backed biotech has chosen a lead drug candidate: …
A look at the R&D landscape in obesity, led by GLP-1s - Fierce …
Mar 19, 2024 · If you’re feeling like overnight obesity became the indication du jour, you’re not alone. Novo Nordisk was granted approval for semaglutide to be marketed as Wegovy for …
After a tough year, Exscientia folds into Recursion - Fierce Biotech
Aug 8, 2024 · But, in 2022, Bayer parted ways on a 240 million euro ($243 million) partnership. And, despite adding a collaboration with Merck KGaA in September 2023 that could top $1 …
Roche bets up to $1B to expand Dyno gene therapy delivery pact
Oct 24, 2024 · The latest deal builds on an initial collaboration Roche signed with Dyno in 2020 to develop central nervous system and liver-directed gene therapies. That first deal could exceed …
Genentech inks $850M upfront deal for Regor's CDK inhibitors
Sep 30, 2024 · Genentech is paying $850 million upfront for Regor Pharmaceuticals’ portfolio of CDK inhibitors, taking ownership of a breast cancer candidate that has shown signs of single …